Total amount: € 0,00
Official Journal of the Italian Society of Social Psychiatry
Indexed/Abstracted in: EMBASE, e-psyche, PsycINFO, Scopus
Online ISSN 1827-1731
Rullo S., Parisi M.
Background. The clinical picture of dysthymia is often associated to a long-term decline of social functions. The aim of this paper is to evaluate the efficacy and safety of 150 mg/daily, long-acting venlafaxine, in the treatment of dysthimia in 20 outpatients, in an open-label study, for 3-months.
Methods. The efficacy was defined according to the changes of the HAMD, CGI, VGF (Wilcoxon test) scores. The safety was defined by the occurrence of side effects, during the period of treatment.
Results. The significant changes of HAMD, CGI, VGF began, respectively, at 30, 60 and 90 days. The use of venlafaxine was also related to a high safety.
Conclusions. The long-acting venlafaxine showed an efficacy and a high safety in the treatment of dysthymia.